Skip to main content
. Author manuscript; available in PMC: 2020 Jun 10.
Published in final edited form as: Int Forum Allergy Rhinol. 2018 Feb;8(2):108–352. doi: 10.1002/alr.22073

TABLE IX.B.7.

Evidence for the use of omalizumab as monotherapy in the treatment of allergic rhinitis (Level 1a and 1b studies with clinical endpoints only)

Study Year LOE Study design Study groups Clinical endpoint Conclusion
Tsabouri et al.1391 2014 1a SR of RCTs, with homogeneity

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication, QOL Omalizumab was superior to placebo. Omalizumab was generally well tolerated.
Okubo et al.1395 2006 1b RCT

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication Efficacy and tolerability in cedar pollen AR.
Chervinsky et al.1394 2003 1b RCT

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication, QOL Efficacy and tolerability in PAR.
Casale et al.1393 2001 1b RCT

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication, QOL Dose-finding trial, 300-mg dose effective in improving symptoms and QOL compared to placebo.
Adelroth et al.1392 2000 1b RCT

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication, QOL Omalizumab was significantly superior to placebo in improving symptoms and QOL. Well tolerated.
Casale et al.1396 1997 1b RCT

  1. Omalizumab;

  2. Placebo

 Symptom score, rescue medication, QOL First dose-finding study, safety confirmed.

AR = allergic rhinitis; LOE = level of evidence; PAR = perennial allergic rhinitis; QOL = quality of life; RCT = randomized controlled trial; SR = systematic review.